Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Filings indexed 378 across all filing types
Latest filing 2025-06-05 Legal Proceedings Report
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)
Legal Proceedings Report Classification · 1% confidence The document is a regulatory filing from a Korean company (Celestra) regarding a legal proceeding ('소송등의제기ㆍ신청'). It details a lawsuit involving a claim for early redemption of convertible bonds. Since the document specifically reports on legal proceedings, lawsuits, and regulatory-related disputes, it falls under the 'Legal Proceedings Report' category.
2025-06-05 Korean
소송등의제기ㆍ신청(일정금액이상의청구) (지급명령(전환사채 조기상환청구))
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory filing regarding a legal proceeding (a lawsuit/litigation) involving a claim for early redemption of convertible bonds. It details the plaintiff, the claim amount, the court, and the company's response (filing an objection to a payment order). This falls directly under the category of legal proceedings or litigation reports.
2025-05-28 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 1% confidence The document is a regulatory filing from a Korean company (Celestra) regarding the rescheduling of an Extraordinary General Meeting (EGM). It details the change in date for the meeting and the agenda items (appointment of an outside director). Since this document is a formal notice of a shareholder meeting and its procedural details, it falls under the category of Proxy Solicitation & Information Statement (PSI), as it provides shareholders with the necessary information regarding the upcoming meeting.
2025-05-21 Korean
소송등의판결ㆍ결정(일정금액이상의청구) (지급명령(전환사채 조기상환청구))
Legal Proceedings Report Classification · 1% confidence The document is a formal regulatory disclosure regarding a court judgment (payment order) concerning a claim for early redemption of convertible bonds. It details the legal case, the amount claimed (7 billion KRW), the court involved, and the company's planned response. This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2025-05-21 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Celestra' (formerly Clinomics) for the period of 2025-01-01 to 2025-03-31. It contains detailed business descriptions, financial management policies, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). It is not a mere announcement or certification, as it provides substantive operational and financial context. Q1 2025
2025-05-15 Korean
[기재정정]분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Celestra' (formerly Clinomics). It contains detailed financial data, including corrected financial statements, notes to the financial statements, and management's discussion of business operations. It is a comprehensive financial report for a period shorter than a full fiscal year (Q1 2025), fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.